Seaport Therapeutics receives up to USD 15 million from ARPA-H to develop GlyphCele, a lymphatic-targeted oral therapy designed to treat metabolic disease and pancreatic cancer by restoring gut lymphatic function.
Advanced Research Projects Agency For Health | 06/03/2026 | By News Bureau | 112
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy